AP
VRTX icon

AHL Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

AHL Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-19,146
Closed -$2.91M – 1378
2017
Q3 		$2.91M Buy
19,146
+12,031
+169% +$1.81M 0.05% 548
2017
Q2 		$916K Buy
+7,115
New +$856K 0.02% 793
2015
Q4 		– Sell
-1,947
Closed -$202K – 774
2015
Q3 		$202K Buy
+1,947
New +$250K 0.03% 661

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AHL Partners's VRTX Position: Q4 2017 in Review

AHL Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 19,146 shares — an estimated $2.91M sold.

AHL Partners first reported a position in VRTX in Q3 2015 and held it in 3 quarters. The position peaked at $2.91M in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • AHL Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 19,146 Vertex Pharmaceuticals shares in Q4 2017, an estimated $2.91M.
  • AHL Partners first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • AHL Partners's Vertex Pharmaceuticals position peaked at $2.91M in Q3 2017.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.